Skip to main
FATE
FATE logo

Fate Therapeutics (FATE) Stock Forecast & Price Target

Fate Therapeutics (FATE) Analyst Ratings

Based on 26 analyst ratings
Buy
Strong Buy 31%
Buy 23%
Hold 38%
Sell 4%
Strong Sell 4%

Bulls say

Fate Therapeutics Inc is recognized for its innovative approach to developing iPSC-derived NK cell therapies, which presents significant advantages in terms of off-the-shelf availability, cost-effective large-scale manufacturing, and adaptability in genetic modifications. Recent clinical updates indicate positive early results with FT819 and FT825, showcasing tolerability and safety in patients, which enhances the company's credibility in the competitive biopharmaceutical landscape. Additionally, strategic FDA approvals to expand patient eligibility and initiate multi-dose treatments could potentially boost enrollment and accelerate the advancement of its clinical programs, signaling an optimistic trajectory for the company's future growth.

Bears say

The financial outlook for Fate Therapeutics Inc. appears negative due to a combination of operational challenges and mixed clinical results. While operational expenditures showed a slight decrease of 2% year-over-year before considering a significant impairment charge, the underlying issues remain concerning. Specifically, the company's initial clinical results for its NK-cell program revealed limited efficacy in treating certain lymphomas and highlighted a lack of sustained responses, raising doubts about the viability of its cell therapy pipeline amid increasing competitive pressures and potential regulatory hurdles.

Fate Therapeutics (FATE) has been analyzed by 26 analysts, with a consensus rating of Buy. 31% of analysts recommend a Strong Buy, 23% recommend Buy, 38% suggest Holding, 4% advise Selling, and 4% predict a Strong Sell.

This aggregate rating is based on analysts' research of Fate Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Fate Therapeutics (FATE) Forecast

Analysts have given Fate Therapeutics (FATE) a Buy based on their latest research and market trends.

According to 26 analysts, Fate Therapeutics (FATE) has a Buy consensus rating as of Aug 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10.60, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10.60, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Fate Therapeutics (FATE)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.